导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -5.62% | 3417/4773 |
| 近一周 | -3.02% | 3559/5462 |
| 近一月 | -7.96% | 4050/5421 |
| 近一季 | 4.46% | 311/5209 |
| 近半年 | -5.76% | 2944/4920 |
| 近一年 | -16.00% | 3747/4366 |
| 近两年 | 18.21% | 2681/2954 |
| 近三年 | -8.47% | 2017/2253 |
| 成立以来 | 31.12% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.63% 1895/4961 |
-7.97% 3818/5312 |
- - |
- - |
| 2025 | 6.78% 2945/4813 |
2.61% 1310/3635 |
3.18% 1123/4076 |
10.03% 3322/4524 |
-8.34% 3905/4813 |
| 2024 | -10.41% 2340/3463 |
-10.37% 2336/2808 |
-7.38% 2076/3014 |
16.87% 1328/3129 |
-7.66% 2785/3463 |
| 2023 | -9.84% 1236/2656 |
1.82% 1505/2280 |
-8.44% 1996/2385 |
-2.77% 748/2515 |
-0.53% 221/2655 |
| 2022 | -17.69% 621/2207 |
-12.65% 645/1919 |
-0.62% 1641/2016 |
-13.80% 976/2113 |
10.00% 186/2208 |
| 2021 | 1.51% 668/1822 |
-0.92% 407/1255 |
12.04% 351/1330 |
-10.90% 1247/1466 |
2.64% 548/1822 |
| 2020 | 41.54% 288/1250 |
8.56% 31/1028 |
29.43% 76/1067 |
2.02% 1013/1164 |
-1.26% 1098/1184 |
| 2019 | 28.46% 520/1092 |
25.55% 459/739 |
-7.42% 557/788 |
5.92% 134/850 |
4.34% 808/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 国联安中证医药100C VS. 长安沪深300非周期A(740101) |